HRP20030575B1 - Preparacija nekristalnog atorvastatin kalcija - Google Patents

Preparacija nekristalnog atorvastatin kalcija

Info

Publication number
HRP20030575B1
HRP20030575B1 HR20030575A HRP20030575A HRP20030575B1 HR P20030575 B1 HRP20030575 B1 HR P20030575B1 HR 20030575 A HR20030575 A HR 20030575A HR P20030575 A HRP20030575 A HR P20030575A HR P20030575 B1 HRP20030575 B1 HR P20030575B1
Authority
HR
Croatia
Prior art keywords
atorvastatin
protecting group
water
group
solution
Prior art date
Application number
HR20030575A
Other languages
English (en)
Croatian (hr)
Inventor
Sorsak Gorazd
Original Assignee
Lek Pharmaceutical And Chemical Company D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceutical And Chemical Company D.D. filed Critical Lek Pharmaceutical And Chemical Company D.D.
Publication of HRP20030575A2 publication Critical patent/HRP20030575A2/hr
Publication of HRP20030575B1 publication Critical patent/HRP20030575B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20030575A 2001-01-23 2002-01-22 Preparacija nekristalnog atorvastatin kalcija HRP20030575B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200100010A SI20814A (sl) 2001-01-23 2001-01-23 Priprava amorfnega atorvastatina
PCT/IB2002/000161 WO2002059087A1 (en) 2001-01-23 2002-01-22 Preparation of non-crystalline atorvastatin calcium

Publications (2)

Publication Number Publication Date
HRP20030575A2 HRP20030575A2 (en) 2005-06-30
HRP20030575B1 true HRP20030575B1 (hr) 2011-10-31

Family

ID=20432812

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030575A HRP20030575B1 (hr) 2001-01-23 2002-01-22 Preparacija nekristalnog atorvastatin kalcija

Country Status (27)

Country Link
US (2) US6750353B2 (https=)
EP (1) EP1373202B1 (https=)
JP (1) JP4336106B2 (https=)
KR (1) KR100882066B1 (https=)
CN (1) CN1260213C (https=)
AT (1) ATE294159T1 (https=)
AU (1) AU2002219455B2 (https=)
BG (1) BG108017A (https=)
BR (1) BR0206637A (https=)
CA (1) CA2435954C (https=)
CZ (1) CZ20031988A3 (https=)
DE (1) DE60203894T2 (https=)
DK (1) DK1373202T3 (https=)
EE (1) EE05270B1 (https=)
ES (1) ES2240748T3 (https=)
HR (1) HRP20030575B1 (https=)
HU (1) HU227535B1 (https=)
IL (2) IL157068A0 (https=)
MX (1) MXPA03006548A (https=)
PL (1) PL209428B1 (https=)
RS (1) RS51010B (https=)
RU (1) RU2324679C2 (https=)
SI (2) SI20814A (https=)
SK (1) SK286593B6 (https=)
UA (1) UA73829C2 (https=)
WO (1) WO2002059087A1 (https=)
ZA (1) ZA200305307B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622477A1 (en) 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
WO2002068335A2 (en) * 2001-02-27 2002-09-06 Council Of Scientific And Industrial Research Essential oil composition for potable water disinfection
SK16002003A3 (sk) 2001-06-29 2004-12-01 Warner-Lambert Company Llc Kryštalické formy vápenatej soli (2:1) [R-(R*,R*)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín)
WO2005033078A1 (en) * 2003-10-07 2005-04-14 Biocon Limited Process for the production of atorvastatin calcium
HU227124B1 (en) * 2001-09-14 2010-07-28 Egis Gyogyszergyar Nyilvanosan Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin
CN100379723C (zh) 2002-02-19 2008-04-09 特瓦制药工业有限公司 阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
CA2385529A1 (en) * 2002-05-21 2003-11-21 Bernard Charles Sherman Stable dosage forms comprising atorvastatin calcium
CA2520740C (en) * 2003-04-11 2012-06-05 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
EP1648903A2 (en) 2003-07-02 2006-04-26 Egis Gyogyszergyar Rt. Process for the preparation of amorphous form of a platelet aggregation inhibitor drug
AU2003247327A1 (en) * 2003-07-15 2005-01-28 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
JP2007517028A (ja) * 2003-12-29 2007-06-28 レツク・フアーマシユーテイカルズ・デー・デー 非晶質の（４ｒ−シス）−６−［２−［３−フェニル−４−（フェニルカルバモイル）−２−（４−フルオロフェニル）−５−（１−メチルエチル）−ピロール−１−イル］−エチル］−２，２−ジメチル−［１，３］−ジオキサン−４−イル−酢酸を調製する方法
ATE545629T1 (de) 2004-03-17 2012-03-15 Ranbaxy Lab Ltd Verfahren zur herstellung von atorvastatin- calcium in amorpher form
US7875731B2 (en) 2004-05-05 2011-01-25 Pfizer Inc. Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
US8044086B2 (en) * 2004-07-16 2011-10-25 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2701710C (en) 2004-07-20 2013-08-27 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
WO2006011155A1 (en) * 2004-07-26 2006-02-02 Apollo International Limited One pot process for amorphous atorvastain calcium
US7645888B2 (en) 2004-08-27 2010-01-12 Biocon Limited Process for the production of amorphous atorvastatin calcium
AU2005298383A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
ES2270722B1 (es) * 2005-09-15 2008-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de atorvastatina calcica amorfa.
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
ATE466840T1 (de) 2005-11-21 2010-05-15 Warner Lambert Co Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
EP1979313A1 (en) * 2006-01-31 2008-10-15 Jubilant Organosys Limited Process for the preparation of amorphous atorvastatin calcium salt
CN100406438C (zh) * 2006-06-30 2008-07-30 浙江新东港药业股份有限公司 一种无定型阿伐他汀钙的制备方法
US20100113802A1 (en) * 2006-11-02 2010-05-06 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
WO2009052246A1 (en) 2007-10-17 2009-04-23 Ovokaitys, Todd, F. Process for the modification of the solid state of a compound and co-amorphous compositions produced with same
WO2009139730A1 (en) * 2008-05-13 2009-11-19 Ulkar Kimya San. Ve Tic. A.S. Preparation of novel non-crystalline forms of atorvastatin calcium
KR101050722B1 (ko) 2008-12-02 2011-07-21 대웅바이오 주식회사 무정형 아토르바스타틴 칼슘염의 제조방법
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
US20130041162A1 (en) * 2010-04-19 2013-02-14 Dsm Sinochem Pharmaceuticals Netherlands B.V. Production of atorvastatin low in ether impurities
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
CN102796036B (zh) * 2012-09-12 2014-06-04 江苏阿尔法药业有限公司 一种阿托伐他汀钙的制备方法
US10202598B2 (en) 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
US10384985B2 (en) 2014-06-06 2019-08-20 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
US10040728B2 (en) 2014-06-06 2018-08-07 Todd Frank Ovokaitys Methods and compositions for increasing the bioactivity of nutrients
CN113321607A (zh) * 2020-02-28 2021-08-31 北京福元医药股份有限公司沧州分公司 一种阿托伐他汀钙中间体的纯化方法
WO2022126109A1 (en) 2020-12-08 2022-06-16 Ovokaitys Todd Frank Methods and systems for increased production of stem cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003960A1 (en) * 1995-07-17 1997-02-06 Warner-Lambert Company NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1)
WO2000071116A1 (en) * 1999-05-25 2000-11-30 Ranbaxy Laboratories Limited Process for the production of amorphous atorvastatin calcium

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
KR100389518B1 (ko) * 1995-07-17 2003-11-15 워너-램버트 캄파니 엘엘씨 결정질[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산헤미칼슘염(아토르바스타틴)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003960A1 (en) * 1995-07-17 1997-02-06 Warner-Lambert Company NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1)
WO2000071116A1 (en) * 1999-05-25 2000-11-30 Ranbaxy Laboratories Limited Process for the production of amorphous atorvastatin calcium

Also Published As

Publication number Publication date
ATE294159T1 (de) 2005-05-15
PL361763A1 (en) 2004-10-04
US7074940B2 (en) 2006-07-11
IL157068A (en) 2009-09-01
KR20030077003A (ko) 2003-09-29
SI20814A (sl) 2002-08-31
JP4336106B2 (ja) 2009-09-30
YU56803A (sh) 2006-05-25
CN1487921A (zh) 2004-04-07
SK286593B6 (sk) 2009-01-07
UA73829C2 (en) 2005-09-15
HUP0302797A3 (en) 2009-09-28
EP1373202A1 (en) 2004-01-02
KR100882066B1 (ko) 2009-02-10
DE60203894D1 (de) 2005-06-02
HU227535B1 (en) 2011-08-29
AU2002219455B2 (en) 2007-04-26
RU2003124962A (ru) 2005-01-10
CZ20031988A3 (cs) 2003-11-12
BR0206637A (pt) 2004-08-03
US6750353B2 (en) 2004-06-15
PL209428B1 (pl) 2011-08-31
WO2002059087A1 (en) 2002-08-01
RU2324679C2 (ru) 2008-05-20
CA2435954A1 (en) 2002-08-01
SK9082003A3 (en) 2003-12-02
MXPA03006548A (es) 2004-10-15
HUP0302797A2 (hu) 2003-11-28
EE200300333A (et) 2003-10-15
US20030109569A1 (en) 2003-06-12
BG108017A (bg) 2004-08-31
ES2240748T3 (es) 2005-10-16
SI1373202T1 (sl) 2005-12-31
DE60203894T2 (de) 2006-01-19
US20040072895A1 (en) 2004-04-15
CA2435954C (en) 2008-06-03
ZA200305307B (en) 2004-07-09
IL157068A0 (en) 2004-02-08
EE05270B1 (et) 2010-02-15
CN1260213C (zh) 2006-06-21
EP1373202B1 (en) 2005-04-27
RS51010B (sr) 2010-10-31
HRP20030575A2 (en) 2005-06-30
JP2005503997A (ja) 2005-02-10
DK1373202T3 (da) 2005-05-17

Similar Documents

Publication Publication Date Title
HRP20030575B1 (hr) Preparacija nekristalnog atorvastatin kalcija
BRPI0408492A (pt) processo para preparar ditioésteres
JP2005503997A5 (https=)
DK1257577T3 (da) Fremgangsmåde til oplösning af glucagon som peptidforbindelse
BRPI0402986A (pt) Processo para a preparação de subóxido de nióbio
RU2018143237A (ru) Катионный липид
ES2143443T3 (es) Espesantes polimeros para composiciones acuosas.
NZ335196A (en) Biphasal compositions and method for removing paint from a substrate
ATE320424T1 (de) Verfahren zu herstellung von citalopram
DK1334116T3 (da) En fremgangsmåde til fremstilling af polyphenoliske adhæsive proteiner
DE50306161D1 (de) Silikon-in-Wasser-Emulsion enthaltend spezifisches Polyether-Polydimethylsiloxan-Copolymer
DE602005011501D1 (de) Wässrige Dispersion von Nanokapseln mit einem öligen Kern und deren Herstellungsverfahren
ATE345766T1 (de) Topische zusammensetzungen mit einer äusseren ölphase und verfahren zu deren herstellung
De Rosa et al. First synthesis of 2-aminopyrrole and simple 1-substituted-2-aminopyrroles. Observation of fast proton exchange at C-5.
KR970703307A (ko) 아미노술폰산 유도체, 의사펩티드 합성으로의 용도 및 이들의 제조 방법(derivatives of aminosulfonic acids, utilization of the same in the synthesis of pseudopeptides and process for their preparation)
DK1380639T3 (da) Fremgangsmåde til fremstilling af en vandig-alkoholisk oplösning
DE60306686D1 (de) Synthetische verdickungsmittel für kosmetika
RU2007122353A (ru) Способ получения гидробромида галантамина
CA2460970A1 (en) Processes for preparing crystalline and amorphous mupirocin calcium
KR920002510A (ko) 4-하이드록시부틸 (메트)아크릴레이트의 제조방법
KR950032223A (ko) 유기황 금 화합물, 이의 제조방법 및 이의 용도
EP0402935A3 (en) Method of producing n-alkylaminophenols
Peralta-Hernández et al. A practical one-pot radical-ionic sequence for the preparation of epoxides: application to the synthesis of unnatural polyhydroxylated alkaloids
RU98111764A (ru) Способ получения соли клавулановой кислоты
RU99106648A (ru) Пастообразный концентрат для напитка

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20111222

Year of fee payment: 11

PBON Lapse due to non-payment of renewal fee

Effective date: 20130123